Skip to main content

Table 1 Option B+ stepped wedge study outcomes measures

From: Early ART initiation among HIV-positive pregnant women in central Mozambique: a stepped wedge randomized controlled trial of an optimized Option B+ approach

Study measure

Numerator/denominator

1. First month ART pharmacy refill rates for newly diagnosed HIV-positive pregnant women

\( \frac{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}}{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}\ \mathrm{that}\ \mathrm{refill}\ \mathrm{their}\ \mathrm{ART}\ \mathrm{prescription}\ \mathrm{within}\ 45\ \mathrm{days}\ \mathrm{of}\ \mathrm{diagnosis}} \)

2. 90-day ART pharmacy refill rates for newly diagnosed HIV-positive pregnant women

\( \frac{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}}{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}\ \mathrm{that}\ \mathrm{routinely}\ \mathrm{refill}\ \mathrm{the}\mathrm{ir}\ \mathrm{ART}\ \mathrm{medications}\ \mathrm{during}\ \mathrm{the}\ 90\ \mathrm{days}\ \mathrm{after}\ \mathrm{the}\mathrm{ir}\ \mathrm{diagnosis}} \)

3. The percentage of newly diagnosed HIV-positive pregnant women that initiate ART within 14 days

\( \frac{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}}{\#\ \mathrm{of}\ \mathrm{newly}\ \mathrm{diagnosed}\ \mathrm{H}\mathrm{I}\mathrm{V}\hbox{-} \mathrm{positive}\ \mathrm{pregnant}\ \mathrm{women}\ \mathrm{that}\ \mathrm{initiate}\ \mathrm{ART}\ \mathrm{within}\ 14\ \mathrm{days}\ \mathrm{of}\ \mathrm{their}\ \mathrm{diagnosis}} \)

  1. ART anti-retroviral therapy, HIV human immunodeficiency virus, PMTCT prevention of maternal to child transmission of HIV.